Recchiuti Antonio, Patruno Sara, Plebani Roberto, Romano Mario
Laboratory of Molecular Medicine, Center on Advanced Studies and Technology (CAST), Department of Medical, Oral e Biotechnological Sciences, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.
Front Pharmacol. 2020 Jul 29;11:1129. doi: 10.3389/fphar.2020.01129. eCollection 2020.
Despite the high expectations associated with the recent introduction of CFTR modulators, airway inflammation still remains a relevant clinical issue in cystic fibrosis (CF). The classical anti-inflammatory drugs have shown very limited efficacy, when not being harmful, raising the question of whether alternative approaches should be undertaken. Thus, a better knowledge of the mechanisms underlying the aberrant inflammation observed in CF is pivotal to develop more efficacious pharmacology. In this respect, the observation that endogenous proresolving pathways are defective in CF and that proresolving mediators, physiologically generated during an acute inflammatory reaction, do not completely suppress inflammation, but promote resolution, tissue healing and microbial clearance, without compromising immune host defense mechanisms, opens interesting therapeutic scenarios for CF. In this mini-review, we present the current knowledge and perspectives of proresolving pharmacology in CF, focusing on the specialized proresolving lipid mediators and selected peptides.
尽管近期引入的CFTR调节剂带来了很高期望，但气道炎症在囊性纤维化（CF）中仍然是一个相关的临床问题。经典的抗炎药物疗效非常有限，甚至还可能有害，这就引发了是否应采取替代方法的问题。因此，深入了解CF中异常炎症背后的机制对于开发更有效的药物至关重要。在这方面，观察到CF中内源性促消退途径存在缺陷，并且在急性炎症反应中生理产生的促消退介质并不能完全抑制炎症，而是促进炎症消退、组织愈合和微生物清除，同时又不损害免疫宿主防御机制，这为CF开启了有趣的治疗前景。在本综述中，我们介绍了CF中促消退药理学的当前知识和观点，重点关注专门的促消退脂质介质和选定的肽。
